The Technical Analyst
MEI Pharma Inc [MEIP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
MEI Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.92% $3.23
America/New_York / 25 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.52 mill |
| EPS: | 2.98 |
| P/E: | 1.080 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 6.66 mill |
| Avg Daily Volume: | 0.0214 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 1.080 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.18x |
| Company: PE 1.080 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.98 - 3.48 ( +/- 7.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-18 | Flynn James P | Buy | 10 000 | Stock Option (Right to Buy) |
| 2023-12-18 | Flynn James P | Buy | 6 700 | Stock Option (Right to Buy) |
| 2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
| 2023-12-18 | Wood Steven D | Buy | 6 700 | Stock Option (Right to Buy) |
| 2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 93.19 |
| Last 96 transactions |
| Buy: 9 932 993 | Sell: 849 643 |
Forecast:
14:11 - $3.23
Live Trading Signals (every 1 min)
Forecast
1: 12:41 - $3.23
Forecast 2: 13:31 - $3.23
Forecast 3: 14:11 - $3.23
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.23 (-0.92% ) |
| Volume | 0.0111 mill |
| Avg. Vol. | 0.0214 mill |
| % of Avg. Vol | 52.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MEIP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-11 08:02:00 - Press Release
Mei Pharma Board Of Directors Aligns On Strategy To Advance Voruciclib And Me-344
San diego--(business wire)--mei pharma, inc. (nasdaq: meip), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the company's board of directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and me-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new me-344 formulation for phase 1 study. additiona.
2024-04-11 08:00:00 - Press Release
Mei Pharma Reports Initial Data From Clinical Study Evaluating Me-344 In Combination With Bevacizumab (avastin®) In Relapsed Metastatic Colorectal Cancer Patients
San diego--(business wire)--mei pharma, inc. (nasdaq: meip), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer (“mcrc”) in cohort 1 of the ongoing phase 1b study evaluating me-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“oxphos”), in combination with bevacizumab (avastin®) ha.
2024-04-10 08:00:00 - Press Release
Mei Pharma To Present At The Stifel 2024 Virtual Targeted Oncology Forum
San diego--(business wire)--mei pharma, inc. (nasdaq: meip), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that david urso, president and chief executive officer of mei pharma, will participate in a fireside chat at the stifel 2024 virtual targeted oncology forum on tuesday, april 16 at 1:30 pm eastern time. investors and the general public are invited to listen to a live webc.
2024-02-15 13:06:00 - Press Release
Glancy Prongay & Murray Llp Announces Investigation Of Mei Pharma, Inc. (meip)
New york--(business wire)--glancy prongay & murray llp (“gpm”) announces its investigation of mei pharma, inc. (nasdaq: meip) concerning the company and its directors' and officers' possible violations of state laws. if you own mei pharma stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact tom kennedy, of gpm, 230 park avenue, suite 358, new york, ny 10169 at tkennedy.
2024-02-13 17:05:00 - Press Release
Mei Pharma Reports Second Quarter Fiscal Year 2024 Results And Operational Highlights
San diego--(business wire)--mei pharma, inc. (nasdaq: meip), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended december 31, 2023, and highlighted recent corporate events. “in the ongoing clinical studies for both voruciclib, our oral cdk9 inhibitor, and me-344, our inhibitor of mitochondrial oxidative phosphorylation, we are gratified by s.
Latest News
2024-02-13 19:16:11 - Zacks Investment Research
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to earnings of $1.60 per share a year ago.
2024-01-16 17:00:00 - Business Wire
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gast.
2023-09-29 13:32:29 - Zacks Investment Research
All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-26 19:47:02 - Seeking Alpha
MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Call Participants Yale Jen - Laidlaw & Company Stephen Willey - Stifel Operator Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today.
2023-06-15 12:08:00 - Business Wire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
2023-05-11 19:02:38 - Zacks Investment Research
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.
2023-02-09 19:35:18 - Zacks Investment Research
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-14 18:48:22 - Zacks Investment Research
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-09-08 21:00:05 - Seeking Alpha
MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer David Urso - Chief Operating Officer and General Counsel Richard Ghalie - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Robyn Karnauskas - Truist Yale Jen - Laidlaw & Co Nick Abbott - Wells Fargo Operator Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request.
2022-06-17 16:34:52 - PennyStocks
Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.